Answers are grounded in this paper and cite their sources.
Activated hepatic stellate cells (HSCs) undergo transcriptional, epigenetic, and functional reprogramming during hepatic fibrosis. Max-like protein X (MLX), a metabolic transcription factor highly expressed in the liver, has uncharacterized roles in this process. The carbon tetrachloride (CCl₄)-induced hepatic fibrosis model and two HSC lines stimulated by transforming growth factor β1 (TGF-β1) were used for in vivo and in vitro assays, respectively. Integrative multi-omics delineated MLX’s regulatory effect on the global fibrotic landscape. Transcriptome analysis of primary HSCs from fibrotic rat livers indicated that HSC genome alterations depended on MLX-mediated transcriptional regulation. MLX overexpression inhibits HSC activation and attenuates TGF-β1-triggered SMAD2/3 phosphorylation, thereby suppressing the TGF-β/SMAD signaling pathway. MLX binds to the SMAD7 gene and upregulates its transcription. Loss of SMAD7 partially restores α-SMA expression and SMAD2/3 phosphorylation in MLX-overexpressing HSCs, confirming that MLX exerts its inhibitory effect on the TGF-β/SMAD pathway by enhancing the SMAD7-mediated negative feedback. HSC-specific MLX overexpression via adeno-associated virus vectors exerted antifibrotic effects in vivo, as evidenced by reduced collagen deposition and liver fibrotic area. Mechanistically, MLX upregulation results from reduced mRNA-destabilizing elements: AU-rich elements (AREs) and N6-methyladenosine (m6A) modification. ELAV-like RNA binding protein 1 (ELAVL1) stabilized MLX mRNA by binding a conserved ARE (+1055 to +1063) in its 3’UTR. A functional m6A site (+961) adjacent to ARE was demethylated by the upregulated demethylase fat mass and obesity-associated protein (FTO) during HSC activation. Mutation assays confirmed that FTO enhanced MLX mRNA stability in an m6A-ELAVL1-dependent manner, with ELAVL1-MLX binding stability driven by FTO-mediated ELAVL1 upregulation and MLX +961 demethylation. Analysis of human liver fibrosis samples revealed that ELAVL1 and MLX were upregulated in activated HSCs at the reversible stage of liver fibrosis to halt disease progression, whereas their protective roles were attenuated in cirrhotic patients. These findings identify MLX as a novel antifibrotic transcription factor and reveal the FTO/ELAVL1-m6A-MLX axis as a potential therapeutic target for hepatic fibrosis.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: